Lil­ly part­ners with Unit­ed­Health to con­duct 're­al-world' study for its Covid-19 an­ti­body bam­lanivimab

As Eli Lil­ly con­tin­ues to build out da­ta for their FDA-au­tho­rized Covid-19 treat­ment bam­lanivimab, they’ve been seek­ing new part­ners to con­duct more tri­als. And the phar­ma found a big one Fri­day.

Lil­ly an­nounced Fri­day morn­ing that it’s team­ing up with Unit­ed­Health Group, the largest health­care com­pa­ny in the world by rev­enue, in or­der to launch a po­ten­tial­ly mas­sive study — up to 500,000 peo­ple — in in­di­vid­u­als who meet the EUA cri­te­ria. Reg­u­la­tors is­sued the au­tho­riza­tion in ear­ly No­vem­ber for re­cent­ly di­ag­nosed, non-hos­pi­tal­ized pa­tients with mild and mod­er­ate Covid-19.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER